Androgen deprivation therapy (ADT) involves the use of antiandrogens which act as competitive inhibitors for androgen receptors, effectively blocking the androgen-signaling axis critical for prostate cancer cell survival and proliferation [16]. Here, AR is linked to prostate carcinoma.